Trials / Recruiting
RecruitingNCT06951386
The Impact of Daily Intake of Short-chain Fatty Acids on Cardiometabolic Risk Factors in Individuals at Risk for Metabolic Syndrome
The Impact of 12 Weeks Intervention With Plant-based Oat Drink Rich in Short-chain Fatty Acids on Postprandial Lipidemia in Individuals at Risk for Metabolic Syndrome
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- KU Leuven · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
During this study, the effect of short-chain fatty acids on blood lipaedemia, glycemia, anthropometrics, blood pressure and energy expenditure will be investigated.
Detailed description
The goal of this study is to investigate the impact of consuming every day a drink enriched with short-chain fatty acids for 12 weeks on the cardiometabolic health in individuals at risk of metabolic syndrome. This means the investigators are looking for people with overweight and disrupted cholesterol, high blood pressure or elevated blood glucose. The individuals will consume for 12 weeks a drink either enriched with SCFA or a control drink (randomly allocated). Before and after this period (study visit 1 and 4), a study visit will take place in which metabolic parameters will be measured such as blood pressure, body weight, waist- and hip circumference, body composition, energy expenditure, glucose, insulin and blood lipids. After 4 and 8 weeks, anthropometrics, blood pressure and body composition will be measured during a short study visit (study visit 2 and 3).
Conditions
- Energy Expenditure
- Metabolic Syndrome
- Anthropometry
- Body Composition
- Glycemia
- Lipaemia
- Metabolomics
- Blood Pressure
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | with short-chain fatty acids enriched drink | Oat-based drink enriched with 15 g/L short-chain fatty acids |
| DIETARY_SUPPLEMENT | unenriched oat drink | Oat-based drink |
Timeline
- Start date
- 2025-02-11
- Primary completion
- 2026-02-28
- Completion
- 2026-02-28
- First posted
- 2025-04-30
- Last updated
- 2025-05-04
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT06951386. Inclusion in this directory is not an endorsement.